Last progress September 2, 2025 (3 months ago)
Introduced on September 2, 2025 by Chris Pappas
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
This bill would undo recent changes to Medicaid and Medicare drug rules. It cancels changes to Medicaid “cost sharing” so the program would go back to its earlier rules, and it takes back the money that was set aside for those changes. It also restores the earlier policy on rare-disease (“orphan”) drugs in Medicare’s drug price negotiation program, returning to the prior rule about excluding those drugs from negotiation.
In short, it aims to keep Medicaid costs and rare-disease drug rules the same as they were before those recent changes were made.